Animal and human anti-malarial agents
US-10016436-B2 · Jul 10, 2018 · US
Animal and human anti-malarial agents
US10736899B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10736899-B2 |
| Application number | US-201916540248-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 14, 2019 |
| Priority date | Jun 2, 2016 |
| Publication date | Aug 11, 2020 |
| Grant date | Aug 11, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, wherein the compound is (R)-N8-(3-chloro-5-(trifluoromethyl)phenyl)-N2-cyclobutyl-9-(pyrrolidin-3-yl)-9H-purine-2,8-diamine, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof. 2. A pharmaceutical composition comprising an effective amount of (R)-N8-(3-chloro-5-(trifluoromethyl)phenyl)-N2-cyclobutyl-9-(pyrrolidin-3-yl)-9H-purine-2,8-diamine, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle. 3. The pharmaceutical composition of claim 2 , further comprising an effective amount of chloroquine, quinine, quinidine, melfloquine, atovaquone, proguanil, doxycycline, artesunate, artemether, artemisinin, lumefantrine, amodiaquine, hydroxychloroquine, halofantrine, pyrimethamine, sulfadoxine, or primaquine.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
with a four-membered ring · CPC title
- A61K31/52Primary
Purines, e.g. adenine · CPC title
Nitrogen atom · CPC title
not condensed with other rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10736899B2 cover?
- Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods…
- Who is the assignee on this patent?
- Celgene Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/52. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).